{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:20:14Z","timestamp":1791724814066,"version":"4.3.4"},"reference-count":134,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004608","name":"Jiangsu Province Natural Science Foundation","doi-asserted-by":"publisher","award":["BK20241919 WH"],"award-info":[{"award-number":["BK20241919 WH"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012154","name":"Graduate Research and Innovation Projects of Jiangsu Province","doi-asserted-by":"publisher","award":["KYCX24_3292"],"award-info":[{"award-number":["KYCX24_3292"]}],"id":[{"id":"10.13039\/501100012154","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jconrel.2026.114713","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T08:04:47Z","timestamp":1770969887000},"page":"114713","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Nanobodies for inflammatory bowel disease: Miniaturizing solutions"],"prefix":"10.1016","volume":"392","author":[{"given":"Yu-Ting","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua-Shan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Ru","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong-Qin","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan-Min","family":"Zha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Qi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.jconrel.2026.114713_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2023.08.013","article-title":"Incidence of inflammatory bowel disease in urban China: a nationwide population-based study","volume":"21","author":"Xu","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.114713_bb0010","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s12664-023-01430-z","article-title":"Trends of inflammatory bowel disease from the global burden of disease study (1990-2019)","volume":"43","author":"Dharni","year":"2024","journal-title":"Indian J. Gastroenterol.: Offi. J. Indian Soc. Gastroenterol."},{"issue":"3","key":"10.1016\/j.jconrel.2026.114713_bb0015","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-065186","article-title":"Global, regional and national burden of inflammatory bowel disease in 204 countries and territories from 1990 to 2019: a systematic analysis based on the global burden of disease study 2019","volume":"13","author":"Wang","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.jconrel.2026.114713_bb0020","doi-asserted-by":"crossref","first-page":"1032679","DOI":"10.3389\/fpubh.2022.1032679","article-title":"Landscape and predictions of inflammatory bowel disease in China: China will enter the compounding prevalence stage around 2030","volume":"10","author":"Shao","year":"2022","journal-title":"Front. Public Health"},{"issue":"5","key":"10.1016\/j.jconrel.2026.114713_bb0025","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.3904\/kjim.2021.114","article-title":"Improving the care of inflammatory bowel disease (IBD) patients: perspectives and strategies for IBD center management","volume":"36","author":"Park","year":"2021","journal-title":"Korean J. Intern. Med."},{"issue":"10432","key":"10.1016\/j.jconrel.2026.114713_bb0030","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/S0140-6736(23)02586-2","article-title":"Crohn's disease","volume":"403","author":"Dolinger","year":"2024","journal-title":"Lancet (London, England)"},{"issue":"10401","key":"10.1016\/j.jconrel.2026.114713_bb0035","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(23)00966-2","article-title":"Ulcerative colitis","volume":"402","author":"Le Berre","year":"2023","journal-title":"Lancet (London, England)"},{"issue":"6","key":"10.1016\/j.jconrel.2026.114713_bb0040","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S2468-1253(23)00011-0","article-title":"Inflammation and malnutrition in inflammatory bowel disease","volume":"8","author":"Massironi","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"8","key":"10.1016\/j.jconrel.2026.114713_bb0045","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/j.cgh.2024.02.014","article-title":"Dynamic prediction of advanced colorectal neoplasia in inflammatory bowel disease","volume":"22","author":"Wijnands","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.jconrel.2026.114713_bb0050","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1053\/j.gastro.2018.12.009","article-title":"AGA clinical practice guidelines on the Management of Mild-to-Moderate Ulcerative Colitis","volume":"156","author":"Ko","year":"2019","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.jconrel.2026.114713_bb0055","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1053\/j.gastro.2018.12.008","article-title":"AGA technical review on the Management of Mild-to-Moderate Ulcerative Colitis","volume":"156","author":"Singh","year":"2019","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.jconrel.2026.114713_bb0060","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2021.05.047","article-title":"A randomized trial comparing the specific carbohydrate diet to a Mediterranean diet in adults with Crohn\u2019s disease","volume":"161","author":"Lewis","year":"2021","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.jconrel.2026.114713_bb0065","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/S2468-1253(22)00022-X","article-title":"AJM300 (carotegrast methyl), an oral antagonist of \u03b14-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"7","author":"Matsuoka","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"14","key":"10.1016\/j.jconrel.2026.114713_bb0070","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1097\/CM9.0000000000003221","volume":"137","year":"2024","journal-title":"Chin. Med. J."},{"issue":"14","key":"10.1016\/j.jconrel.2026.114713_bb0075","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1097\/CM9.0000000000003222","volume":"137","year":"2024","journal-title":"Chin. Med. J."},{"issue":"13","key":"10.1016\/j.jconrel.2026.114713_bb0080","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s40265-023-01916-2","article-title":"Anti-TNF agents and new biological agents (Vedolizumab and Ustekinumab) in the prevention and treatment of postoperative recurrence after surgery in Crohn\u2019s disease","volume":"83","author":"Gisbert","year":"2023","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.jconrel.2026.114713_bb0085","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S2468-1253(24)00044-X","article-title":"Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn\u2019s disease: 3-year data from the prospective, multicentre PANTS cohort study","volume":"9","author":"Chanchlani","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"7","key":"10.1016\/j.jconrel.2026.114713_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2023.03.001","article-title":"Upadacitinib is effective and safe in both ulcerative colitis and Crohn\u2019s disease: prospective real-world experience","volume":"21","author":"Friedberg","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol.: Off. Clin. Pract. J. Am. Gastroenterol. Assoc."},{"issue":"1","key":"10.1016\/j.jconrel.2026.114713_bb0095","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1186\/s12951-024-02900-y","article-title":"Discovery of nanobodies: a comprehensive review of their applications and potential over the past five years","volume":"22","author":"Alexander","year":"2024","journal-title":"J. Nanobiotechnol."},{"issue":"14","key":"10.1016\/j.jconrel.2026.114713_bb0100","doi-asserted-by":"crossref","first-page":"13044","DOI":"10.1021\/acsnano.3c02403","article-title":"Mechanisms of nanoparticle transport across intestinal tissue: an Oral delivery perspective","volume":"17","author":"Ejazi","year":"2023","journal-title":"ACS Nano"},{"issue":"12","key":"10.1016\/j.jconrel.2026.114713_bb0105","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41551-025-01425-5","article-title":"Engineering multi-specific nano-antibodies for cancer immunotherapy","volume":"9","author":"Fan","year":"2025","journal-title":"Nat. Biomed. Eng."},{"issue":"6428","key":"10.1016\/j.jconrel.2026.114713_bb0110","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/363446a0","article-title":"Naturally occurring antibodies devoid of light chains","volume":"363","author":"Hamers-Casterman","year":"1993","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jconrel.2026.114713_bb0115","doi-asserted-by":"crossref","DOI":"10.1186\/s13550-021-00750-5","article-title":"Nanobody: a promising toolkit for molecular imaging and disease therapy","volume":"11","author":"Bao","year":"2021","journal-title":"EJNMMI Res."},{"issue":"7","key":"10.1016\/j.jconrel.2026.114713_bb0120","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.drudis.2016.04.003","article-title":"Nanobodies as therapeutics: big opportunities for small antibodies","volume":"21","author":"Steeland","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2026.114713_bb0125","series-title":"Annual Review of Biochemistry","first-page":"775","article-title":"Nanobodies: Natural Single-Domain Antibodies","volume":"vol. 82","author":"Muyldermans","year":"2013"},{"issue":"1","key":"10.1016\/j.jconrel.2026.114713_bb0130","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00253-007-1142-2","article-title":"Properties, production, and applications of camelid single-domain antibody fragments","volume":"77","author":"Harmsen","year":"2007","journal-title":"Appl. Microbiol. Biotechnol."},{"issue":"3","key":"10.1016\/j.jconrel.2026.114713_bb0135","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0014-5793(94)80432-X","article-title":"\u2018Camelising\u2019 human antibody fragments: NMR studies on VH domains","volume":"339","author":"Davies","year":"1994","journal-title":"FEBS Lett."},{"issue":"6","key":"10.1016\/j.jconrel.2026.114713_bb0140","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/bab.1340","article-title":"Selection by phage display of nanobodies directed against hypoxia inducible factor-1\u03b1 (HIF-1\u03b1)","volume":"62","author":"Li","year":"2015","journal-title":"Biotechnol. Appl. Biochem."},{"issue":"11","key":"10.1016\/j.jconrel.2026.114713_bb0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050026","article-title":"Direct and dynamic detection of HIV-1 in living cells","volume":"7","author":"Helma","year":"2012","journal-title":"PLoS One"},{"issue":"18","key":"10.1016\/j.jconrel.2026.114713_bb0150","doi-asserted-by":"crossref","first-page":"5333","DOI":"10.1007\/s00216-015-8693-3","article-title":"Anti-idiotypic nanobody as citrinin mimotope from a naive alpaca heavy chain single domain antibody library","volume":"407","author":"Xu","year":"2015","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.jconrel.2026.114713_bb0155","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01603","article-title":"Nanobodies and Nanobody-based human heavy chain antibodies as antitumor therapeutics","volume":"8","author":"Bannas","year":"2017","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.jconrel.2026.114713_bb0160","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1074\/jbc.M111.242818","article-title":"Dual beneficial effect of Interloop disulfide bond for single domain antibody fragments","volume":"287","author":"Govaert","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2026.114713_bb0165","article-title":"Development and characterization of Nanobodies targeting the Kupffer cell","volume":"12","author":"Zheng","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2026.114713_bb0170","first-page":"149978","article-title":"Nanobodies as therapies for loss-of-function misfolding diseases: the example of primary hyperoxaluria type 1","author":"Dindo","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.114713_bb0175","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1038\/s41467-025-60134-4","article-title":"Developing nanobodies as allosteric molecular chaperones of glucocerebrosidase function","volume":"16","author":"Dal Maso","year":"2025","journal-title":"Nat. Commun."},{"issue":"44","key":"10.1016\/j.jconrel.2026.114713_bb0180","article-title":"Engineered cellular vesicles displaying glycosylated Nanobodies for cancer immunotherapy","volume":"63","author":"Wu","year":"2024","journal-title":"Angew. Chem. Int. Ed. Eng."},{"issue":"3","key":"10.1016\/j.jconrel.2026.114713_bb0185","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1636","article-title":"Novel bispecific nanobody mitigates experimental intestinal inflammation in mice by targeting TNF-\u03b1 and IL-23p19 bioactivities","volume":"14","author":"Wang","year":"2024","journal-title":"Clin. Transl. Med."},{"issue":"Supplement_1","key":"10.1016\/j.jconrel.2026.114713_bb0190","doi-asserted-by":"crossref","first-page":"i47","DOI":"10.1093\/ecco-jcc\/jjad212.0026","article-title":"OP26 programmable probiotic local delivery of anti-TNF-\u03b1 nanobody to alleviate DSS-induced colitis","volume":"18","author":"Kang","year":"2024","journal-title":"J. Crohn\u2019s Colitis"},{"issue":"11","key":"10.1016\/j.jconrel.2026.114713_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.105343","article-title":"Bispecific soluble cytokine receptor-nanobody fusions inhibit interleukin (IL-)6 trans-signaling and IL-12\/23 or tumor necrosis factor (TNF) signaling","volume":"299","author":"Gesiorowski","year":"2023","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.jconrel.2026.114713_bb0200","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202115415","article-title":"Nanobodies dismantle post-pyroptotic ASC specks and counteract inflammation in vivo","volume":"14","author":"Bertheloot","year":"2022","journal-title":"EMBO Mol. Med."},{"issue":"6","key":"10.1016\/j.jconrel.2026.114713_bb0205","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202216087","article-title":"ASC nanobodies to counteract the consequences of inflammasome activation","volume":"14","author":"Adriouch","year":"2022","journal-title":"EMBO Mol. Med."},{"issue":"1","key":"10.1016\/j.jconrel.2026.114713_bb0210","doi-asserted-by":"crossref","first-page":"8266","DOI":"10.1038\/s41467-024-52110-1","article-title":"Antagonistic nanobodies implicate mechanism of GSDMD pore formation and potential therapeutic application","volume":"15","author":"Schiffelers","year":"2024","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.jconrel.2026.114713_bb0215","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2174\/1871527317666181114134518","article-title":"Generation and characterization of a functional Nanobody against inflammatory chemokine CXCL10, as a novel strategy for the treatment of multiple sclerosis","volume":"18","author":"Sadeghian-Rizi","year":"2019","journal-title":"CNS Neurol. Disord. Drug Targets"},{"issue":"18","key":"10.1016\/j.jconrel.2026.114713_bb0220","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.3748\/wjg.v29.i18.2733","article-title":"Study of tumor necrosis factor receptor in the inflammatory bowel disease","volume":"29","author":"Souza","year":"2023","journal-title":"World J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.114713_bb0225","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/mi.2009.116","article-title":"Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis","volume":"3","author":"Vandenbroucke","year":"2010","journal-title":"Mucosal Immunol."},{"issue":"4","key":"10.1016\/j.jconrel.2026.114713_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.chom.2023.03.007","article-title":"Engineered Escherichia coli for the in situ secretion of therapeutic nanobodies in the gut","volume":"31","author":"Lynch","year":"2023","journal-title":"Cell Host Microbe"},{"issue":"1","key":"10.1016\/j.jconrel.2026.114713_bb0235","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00253-024-13163-w","article-title":"Dual engineered bacteria improve inflammatory bowel disease in mice","volume":"108","author":"Wu","year":"2024","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.114713_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108685","article-title":"Exogenous Annexin 1 inhibits Th17 cell differentiation induced by anti-TNF treatment via activating FPR2 in DSS-induced colitis","volume":"107","author":"Liu","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.jconrel.2026.114713_bb0245","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3389\/fphar.2018.00266","article-title":"Nanobody-based biologics for modulating purinergic signaling in inflammation and immunity","volume":"9","author":"Menzel","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"366","key":"10.1016\/j.jconrel.2026.114713_bb0250","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf8463","article-title":"Nanobodies that block gating of the P2X7 ion channel ameliorate inflammation","volume":"8","author":"Danquah","year":"2016","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.jconrel.2026.114713_bb0255","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12951-023-02285-4","article-title":"Administration of an AAV vector coding for a P2X7-blocking nanobody-based biologic ameliorates colitis in mice","volume":"22","author":"Abad","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2026.114713_bb0260","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2022.794169","article-title":"Nutraceuticals for the treatment of IBD: current progress and future directions","volume":"9","author":"Ban","year":"2022","journal-title":"Front. Nutr."},{"issue":"6","key":"10.1016\/j.jconrel.2026.114713_bb0265","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12462","article-title":"Milk-derived extracellular vesicles functionalized with anti-tumour necrosis factor-\u03b1 nanobody and anti-microbial peptide alleviate ulcerative colitis in mice","volume":"13","author":"Jing","year":"2024","journal-title":"J. Extracell. Vesicles"},{"issue":"9","key":"10.1016\/j.jconrel.2026.114713_bb0270","doi-asserted-by":"crossref","first-page":"pgae374","DOI":"10.1093\/pnasnexus\/pgae374","article-title":"In situ deposition of nanobodies by an engineered commensal microbe promotes survival in a mouse model of enterohemorrhagic E. coli","volume":"3","author":"Srivastava","year":"2024","journal-title":"PNAS Nexus"},{"key":"10.1016\/j.jconrel.2026.114713_bb0275","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jconrel.2024.07.032","article-title":"Nanotechnology-assisted intracellular delivery of antibody as a precision therapy approach for KRAS-driven tumors","volume":"373","author":"L\u00f3pez-Est\u00e9vez","year":"2024","journal-title":"J. Control. Release"},{"issue":"13","key":"10.1016\/j.jconrel.2026.114713_bb0280","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.cgh.2025.03.030","article-title":"Diagnostic accuracy of noninvasive biomarkers and imaging for evaluating postoperative recurrence in Crohn\u2019s disease","volume":"23","author":"Samnani","year":"2025","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"6","key":"10.1016\/j.jconrel.2026.114713_bb0285","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1515\/cclm-2022-0126","article-title":"Evaluation of a faecal calprotectin method using the OC-SENSOR PLEDIA","volume":"60","author":"O\u2019Driscoll","year":"2022","journal-title":"Clin. Chem. Lab. Med."},{"issue":"1","key":"10.1016\/j.jconrel.2026.114713_bb0290","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12877-018-0767-6","article-title":"Are self-reported gastrointestinal symptoms among older adults associated with increased intestinal permeability and psychological distress?","volume":"18","author":"Ganda Mall","year":"2018","journal-title":"BMC Geriatr."},{"issue":"5","key":"10.1016\/j.jconrel.2026.114713_bb0295","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1007\/s00330-017-5148-6","article-title":"Anatomical road mapping using CT and MR enterography for ultrasound molecular imaging of small bowel inflammation in swine","volume":"28","author":"Wang","year":"2018","journal-title":"Eur. Radiol."},{"issue":"10","key":"10.1016\/j.jconrel.2026.114713_bb0300","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.crohns.2012.10.011","article-title":"Autoantibodies against exocrine pancreas in Crohn\u2019s disease are directed against two antigens: the glycoproteins CUZD1 and GP2","volume":"7","author":"Komorowski","year":"2013","journal-title":"J. Crohns Colitis"},{"issue":"12","key":"10.1016\/j.jconrel.2026.114713_bb0305","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1136\/gut.2008.162495","article-title":"Identification of GP2, the major zymogen granule membrane glycoprotein, as the autoantigen of pancreatic antibodies in Crohn's disease","volume":"58","author":"Roggenbuck","year":"2009","journal-title":"Gut"},{"issue":"9\u201310","key":"10.1016\/j.jconrel.2026.114713_bb0310","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.cca.2010.12.029","article-title":"Autoantibodies to GP2, the major zymogen granule membrane glycoprotein, are new markers in Crohn\u2019s disease","volume":"412","author":"Roggenbuck","year":"2011","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.jconrel.2026.114713_bb0315","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.nbt.2018.03.006","article-title":"Generation and validation of murine monoclonal and camelid recombinant single domain antibodies specific for human pancreatic glycoprotein 2","volume":"45","author":"Schlor","year":"2018","journal-title":"New Biotechnol."},{"issue":"20","key":"10.1016\/j.jconrel.2026.114713_bb0320","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252010874","article-title":"Persistent activation of the P2X7 receptor underlies chronic inflammation and carcinogenic changes in the intestine","volume":"25","author":"Santana","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.jconrel.2026.114713_bb0325","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.mucimm.2022.11.003","article-title":"Macrophages and glia are the dominant P2X7-expressing cell types in the gut nervous system-no evidence for the role of neuronal P2X7 receptors in colitis","volume":"16","author":"Jooss","year":"2023","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.jconrel.2026.114713_bb0330","article-title":"The role of intestinal immune cells and matrix metalloproteinases in inflammatory bowel disease","volume":"13","author":"Mei","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2026.114713_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.bios.2025.117684","article-title":"A disposable VHH-based SPR fiber probe for sensitive and specific detection of MMP-9 in cancer and inflammatory disease","volume":"287","author":"Wu","year":"2025","journal-title":"Biosens. Bioelectron."},{"issue":"5","key":"10.1016\/j.jconrel.2026.114713_bb0340","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1053\/j.gastro.2020.12.030","article-title":"Single-cell transcriptional survey of Ileal-anal pouch immune cells from ulcerative colitis patients","volume":"160","author":"Devlin","year":"2021","journal-title":"Gastroenterology"},{"issue":"8053","key":"10.1016\/j.jconrel.2026.114713_bb0345","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/s41586-024-08441-6","article-title":"CD45-PET is a robust, non-invasive tool for imaging inflammation","volume":"639","author":"Salehi Farid","year":"2025","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.jconrel.2026.114713_bb0350","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/s41577-025-01183-0","article-title":"CD45-PET imaging gives a panoramic view of in vivo immune activity","volume":"25","author":"Djafari Rouhani","year":"2025","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.114713_bb0355","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1038\/s41598-018-23277-7","article-title":"Preclinical development of a novel, orally-administered anti-tumour necrosis factor domain antibody for the treatment of inflammatory bowel disease","volume":"8","author":"Crowe","year":"2018","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.jconrel.2026.114713_bb0360","doi-asserted-by":"crossref","first-page":"14042","DOI":"10.1038\/s41598-019-50545-x","article-title":"Oral anti-tumour necrosis factor domain antibody V565 provides high intestinal concentrations, and reduces markers of inflammation in ulcerative colitis patients","volume":"9","author":"Nurbhai","year":"2019","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.jconrel.2026.114713_bb0365","doi-asserted-by":"crossref","first-page":"19422","DOI":"10.1038\/s41598-021-97236-0","article-title":"Preclinical development of a bispecific TNF\u03b1\/IL-23 neutralising domain antibody as a novel oral treatment for inflammatory bowel disease","volume":"11","author":"Roberts","year":"2021","journal-title":"Sci. Rep."},{"issue":"13","key":"10.1016\/j.jconrel.2026.114713_bb0370","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1111\/bph.14667","article-title":"Inhibition of phosphodiesterase-4 attenuates murine ulcerative colitis through interference with mucosal immunity","volume":"176","author":"Li","year":"2019","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.114713_bb0375","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.apsb.2021.04.007","article-title":"Targeting PDE4 as a promising therapeutic strategy in chronic ulcerative colitis through modulating mucosal homeostasis","volume":"12","author":"Li","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"issue":"11","key":"10.1016\/j.jconrel.2026.114713_bb0380","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1016\/j.cgh.2019.12.032","article-title":"Effects of Apremilast, an Oral inhibitor of phosphodiesterase 4, in a randomized trial of patients with active ulcerative colitis","volume":"18","author":"Danese","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"8","key":"10.1016\/j.jconrel.2026.114713_bb0385","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/j.cgh.2020.10.038","article-title":"Efficacy and safety of extended induction with Tofacitinib for the treatment of ulcerative colitis","volume":"20","author":"Sandborn","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.114713_bb0390","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.cgh.2020.10.004","article-title":"Maintenance of remission with Tofacitinib therapy in patients with ulcerative colitis","volume":"20","author":"Colombel","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"9","key":"10.1016\/j.jconrel.2026.114713_bb0395","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.14309\/ajg.0000000000002860","article-title":"Resolution of rectal bleeding by day 7 in acute severe ulcerative colitis is prognostic for Postdischarge corticosteroid-free clinical remission and endoscopic improvement","volume":"119","author":"Narula","year":"2024","journal-title":"Am. J. Gastroenterol."},{"issue":"7","key":"10.1016\/j.jconrel.2026.114713_bb0400","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/ecco-jcc\/jjaa249","article-title":"Outcomes of Tofacitinib dose reduction in patients with ulcerative colitis in stable remission from the randomised RIVETING trial","volume":"15","author":"Vermeire","year":"2021","journal-title":"J. Crohns Colitis"},{"issue":"4","key":"10.1016\/j.jconrel.2026.114713_bb0405","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/ecco-jcc\/jjac161","article-title":"Disease activity and health-related quality of life relationships with work productivity in patients with ulcerative colitis in OCTAVE induction 1 and 2 and OCTAVE sustain","volume":"17","author":"Targownik","year":"2023","journal-title":"J. Crohns Colitis"},{"issue":"4","key":"10.1016\/j.jconrel.2026.114713_bb0410","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40265-023-01840-5","article-title":"Safety of Janus kinase inhibitors in inflammatory bowel diseases","volume":"83","author":"N\u00fa\u00f1ez","year":"2023","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.jconrel.2026.114713_bb0415","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/ecco-jcc\/jjac141","article-title":"Tofacitinib for the treatment of ulcerative colitis: an integrated summary of up to 7.8 years of safety data from the global clinical Programme","volume":"17","author":"Sandborn","year":"2023","journal-title":"J. Crohns Colitis"},{"issue":"6","key":"10.1016\/j.jconrel.2026.114713_bb0420","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1053\/j.gastro.2020.01.001","article-title":"Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and Meta-analysis","volume":"158","author":"Olivera","year":"2020","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.jconrel.2026.114713_bb0425","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s40265-021-01528-8","article-title":"Targeting Sphingosine-1-phosphate signaling in immune-mediated diseases: beyond multiple sclerosis","volume":"81","author":"P\u00e9rez-Jeldres","year":"2021","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.jconrel.2026.114713_bb0430","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s40265-024-02094-5","article-title":"Targeting the sphingosine-1-phosphate pathway: new opportunities in inflammatory bowel disease management","volume":"84","author":"Kitsou","year":"2024","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.jconrel.2026.114713_bb0435","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.cgh.2023.11.018","article-title":"Cardiovascular safety of Ozanimod in patients with ulcerative colitis: true north and open-label extension analyses","volume":"22","author":"Armuzzi","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"7","key":"10.1016\/j.jconrel.2026.114713_bb0440","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1136\/gutjnl-2018-316702","article-title":"Responsiveness of histological disease activity indices in ulcerative colitis: a post hoc analysis using data from the TOUCHSTONE randomised controlled trial","volume":"68","author":"Jairath","year":"2019","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.jconrel.2026.114713_bb0445","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/gutjnl-2020-322339","article-title":"First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial","volume":"71","author":"Jongsma","year":"2022","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.jconrel.2026.114713_bb0450","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S2468-1253(24)00034-7","article-title":"A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn\u2019s disease (PROFILE): a multicentre, open-label randomised controlled trial","volume":"9","author":"Noor","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"10342","key":"10.1016\/j.jconrel.2026.114713_bb0455","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1016\/S0140-6736(22)00688-2","article-title":"Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial","volume":"399","author":"Sands","year":"2022","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jconrel.2026.114713_bb0460","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S2468-1253(22)00385-5","article-title":"Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn\u2019s disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial","volume":"8","author":"Louis","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.jconrel.2026.114713_bb0465","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/gutjnl-2024-333385","article-title":"Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of GETECCU","volume":"74","author":"Gisbert","year":"2025","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.jconrel.2026.114713_bb0470","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S2468-1253(21)00062-5","article-title":"Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial","volume":"6","author":"Kobayashi","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"4","key":"10.1016\/j.jconrel.2026.114713_bb0475","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1053\/j.gastro.2022.12.042","article-title":"Anti-integrin \u03b1v\u03b26 autoantibodies are a novel biomarker that antedate ulcerative colitis","volume":"164","author":"Livanos","year":"2023","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.jconrel.2026.114713_bb0480","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1136\/gutjnl-2023-331696","article-title":"Fluorescently labelled vedolizumab to visualise drug distribution and mucosal target cells in inflammatory bowel disease","volume":"73","author":"Gabri\u00ebls","year":"2024","journal-title":"Gut"},{"issue":"8","key":"10.1016\/j.jconrel.2026.114713_bb0485","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.cgh.2024.11.013","article-title":"A randomized phase II study of Efmarodocokin alfa, an interleukin-22 agonist, versus Vedolizumab in patients with ulcerative colitis","volume":"23","author":"Danese","year":"2025","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.jconrel.2026.114713_bb0490","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cgh.2024.06.037","article-title":"Mucosal healing with Vedolizumab in patients with chronic Pouchitis: EARNEST, a randomized, double-blind, Placebo-Controlled Trial","volume":"23","author":"Jairath","year":"2025","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"4","key":"10.1016\/j.jconrel.2026.114713_bb0495","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S2468-1253(21)00474-X","article-title":"Treat to target versus standard of care for patients with Crohn\u2019s disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial","volume":"7","author":"Danese","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"13","key":"10.1016\/j.jconrel.2026.114713_bb0500","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.jconrel.2026.114713_bb0505","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/jama.2024.12414","article-title":"Risankizumab for ulcerative colitis: two randomized clinical trials","volume":"332","author":"Louis","year":"2024","journal-title":"Jama"},{"issue":"10080","key":"10.1016\/j.jconrel.2026.114713_bb0510","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/S0140-6736(17)30570-6","article-title":"Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study","volume":"389","author":"Feagan","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jconrel.2026.114713_bb0515","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa2314585","article-title":"Risankizumab versus Ustekinumab for moderate-to-severe Crohn\u2019s disease","volume":"391","author":"Peyrin-Biroulet","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.jconrel.2026.114713_bb0520","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41575-022-00738-z","article-title":"Improving IBD outcomes in the era of many treatment options","volume":"20","author":"Kobayashi","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.jconrel.2026.114713_bb0525","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.cgh.2021.02.025","article-title":"Five-year efficacy and safety of Ustekinumab treatment in Crohn\u2019s disease: the IM-UNITI trial","volume":"20","author":"Sandborn","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.114713_bb0530","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjaf005","article-title":"Risankizumab efficacy and safety based on prior inadequate response or intolerance to advanced therapy: post hoc analysis of the INSPIRE and COMMAND phase 3 studies","volume":"19","author":"Panaccione","year":"2025","journal-title":"J. Crohns Colitis"},{"issue":"1","key":"10.1016\/j.jconrel.2026.114713_bb0535","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s11671-025-04200-2","article-title":"Trends in nanobody technology in industrialization","volume":"20","author":"Wu","year":"2025","journal-title":"Discov. Nano"},{"key":"10.1016\/j.jconrel.2026.114713_bb0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.bej.2025.109887","article-title":"Vitamin supplementation for enhanced production of therapeutic nanobody in E.Coli","volume":"223","author":"Katiyar","year":"2025","journal-title":"Biochem. Eng. J."},{"key":"10.1016\/j.jconrel.2026.114713_bb0545","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.3389\/fimmu.2017.01802","article-title":"Single-domain antibodies as therapeutics against human viral diseases","volume":"8","author":"Wu","year":"2017","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.114713_bb0550","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1186\/s12951-024-02904-8","article-title":"Recombinant Lactococcus lactis secreting FliC protein nanobodies for resistance against Salmonella enteritidis invasion in the intestinal tract","volume":"22","author":"Yang","year":"2024","journal-title":"J. Nanobiotechnol."},{"issue":"2","key":"10.1016\/j.jconrel.2026.114713_bb0555","doi-asserted-by":"crossref","DOI":"10.1002\/mbo3.1270","article-title":"Recombinant Limosilactobacillus (Lactobacillus) delivering nanobodies against Clostridium perfringens NetB and alpha toxin confers potential protection from necrotic enteritis","volume":"11","author":"Gangaiah","year":"2022","journal-title":"MicrobiologyOpen"},{"issue":"8","key":"10.1016\/j.jconrel.2026.114713_bb0560","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1021\/acssynbio.4c00036","article-title":"Engineering a novel probiotic toolkit in Escherichia coli Nissle 1917 for sensing and mitigating gut inflammatory diseases","volume":"13","author":"Weibel","year":"2024","journal-title":"ACS Synth. Biol."},{"issue":"7","key":"10.1016\/j.jconrel.2026.114713_bb0565","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1007\/s10620-025-09008-9","article-title":"Engineered probiotic Saccharomyces boulardii reduces colitis-associated colorectal Cancer burden in mice","volume":"70","author":"Culpepper","year":"2025","journal-title":"Dig. Dis. Sci."},{"issue":"37","key":"10.1016\/j.jconrel.2026.114713_bb0570","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2320482121","article-title":"Inflammation-oriented montmorillonite adjuvant enhanced oral delivery of anti-TNF-\u03b1 nanobody against inflammatory bowel disease","volume":"121","author":"Huang","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"15","key":"10.1016\/j.jconrel.2026.114713_bb0575","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ade5041","article-title":"Milk-derived extracellular vesicles protect intestinal barrier integrity in the gut-liver axis","volume":"9","author":"Tong","year":"2023","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.jconrel.2026.114713_bb0580","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12951-025-03292-3","article-title":"Ginseng exosomes modulate M1\/M2 polarisation by activating autophagy and target IKK\/I\u043aB\/NF-\u043aB to alleviate inflammatory bowel disease","volume":"23","author":"Yang","year":"2025","journal-title":"J. Nanobiotechnol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.114713_bb0585","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s12951-023-01951-x","article-title":"Human umbilical cord mesenchymal stem cells derived exosome shuttling mir-129-5p attenuates inflammatory bowel disease by inhibiting ferroptosis","volume":"21","author":"Wei","year":"2023","journal-title":"J. Nanobiotechnol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.114713_bb0590","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1186\/s12951-023-02176-8","article-title":"Potential therapeutic effects of milk-derived exosomes on intestinal diseases","volume":"21","author":"Cui","year":"2023","journal-title":"J. Nanobiotechnol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.114713_bb0595","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1186\/s12951-023-02173-x","article-title":"Probing milk extracellular vesicles for intestinal delivery of RNA therapies","volume":"21","author":"Zhang","year":"2023","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2026.114713_bb0600","doi-asserted-by":"crossref","DOI":"10.3402\/jev.v5.31053","article-title":"Display of GPI-anchored anti-EGFR nanobodies on extracellular vesicles promotes tumour cell targeting","volume":"5","author":"Kooijmans","year":"2016","journal-title":"J. Extracell. Vesicles"},{"issue":"5","key":"10.1016\/j.jconrel.2026.114713_bb0605","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1039\/C7NR06966A","article-title":"Recombinant phosphatidylserine-binding nanobodies for targeting of extracellular vesicles to tumor cells: a plug-and-play approach","volume":"10","author":"Kooijmans","year":"2018","journal-title":"Nanoscale"},{"issue":"1","key":"10.1016\/j.jconrel.2026.114713_bb0610","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12951-025-03169-5","article-title":"Unveiling the new chapter in nanobody engineering: advances in traditional construction and AI-driven optimization","volume":"23","author":"Liu","year":"2025","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2026.114713_bb0615","article-title":"NanoAbLLaMA: construction of nanobody libraries with protein large language models","volume":"13","author":"Wang","year":"2025","journal-title":"Front. Chem."},{"key":"10.1016\/j.jconrel.2026.114713_bb0620","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.91512.4","article-title":"Accurate prediction of CDR-H3 loop structures of antibodies with deep learning","volume":"12","author":"Chen","year":"2024","journal-title":"Elife"},{"issue":"6","key":"10.1016\/j.jconrel.2026.114713_bb0625","first-page":"101260","article-title":"EvoNB: a protein language model-based workflow for Nanobody mutation prediction and optimization","volume":"15","author":"Xiong","year":"2025","journal-title":"J. Pharmaceutic. Analy."},{"issue":"12","key":"10.1016\/j.jconrel.2026.114713_bb0630","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1038\/s42256-024-00940-5","article-title":"Nanobody\u2013antigen interaction prediction with ensemble deep learning and prompt-based protein language models","volume":"6","author":"Deng","year":"2024","journal-title":"Nat. Mach. Intell."},{"issue":"3","key":"10.1016\/j.jconrel.2026.114713_bb0635","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/s41551-023-01093-3","article-title":"Rapid discovery of high-affinity antibodies via massively parallel sequencing, ribosome display and affinity screening","volume":"8","author":"Porebski","year":"2024","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.jconrel.2026.114713_bb0640","article-title":"Anti-PD-1 nanobody-armored MSLN CAR-T therapy for malignant mesothelioma: preclinical and clinical studies","author":"Sun","year":"2025","journal-title":"Adv. Sci. (Weinh.)"},{"issue":"1","key":"10.1016\/j.jconrel.2026.114713_bb0645","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13045-021-01095-1","article-title":"Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair\/microsatellite instability high solid tumors","volume":"14","author":"Li","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.114713_bb0650","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41392-024-01991-1","article-title":"Envafolimab plus lenvatinib and transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a prospective, single-arm, phase II study","volume":"9","author":"Chen","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"4","key":"10.1016\/j.jconrel.2026.114713_bb0655","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jaci.2024.05.027","article-title":"A novel inhalable nanobody targeting IL-4R\u03b1 for the treatment of asthma","volume":"154","author":"Zhu","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.114713_bb0660","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2024.2322562","article-title":"A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapy","volume":"16","author":"Frey","year":"2024","journal-title":"MAbs"},{"issue":"1","key":"10.1016\/j.jconrel.2026.114713_bb0665","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1038\/s41467-024-46025-0","article-title":"Targeted delivery of fc-fused PD-L1 for effective management of acute and chronic colitis","volume":"15","author":"Tang","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.114713_bb0670","first-page":"273","article-title":"Injection of ROS-responsive hydrogel loaded with IL-1\u03b2-targeted nanobody for ameliorating myocardial infarction","volume":"46","author":"Wang","year":"2025","journal-title":"Bioact. Mater."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836592600115X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836592600115X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T08:43:40Z","timestamp":1787129020000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016836592600115X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":134,"alternative-id":["S016836592600115X"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.114713","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanobodies for inflammatory bowel disease: Miniaturizing solutions","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.114713","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114713"}}